Portola Pharmaceuticals, Inc.
PTLA
PTLA was delisted on the 1st of July, 2020.
167 hedge funds and large institutions have $1.08B invested in Portola Pharmaceuticals, Inc. in 2016 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 75 increasing their positions, 52 reducing their positions, and 41 closing their positions.
152% more call options, than puts
Call options by funds: $40.4M | Put options by funds: $16M
44% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 52
12% less funds holding
Funds holding: 190 → 167 (-23)
54% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 41
59% less capital invested
Capital invested by funds: $2.66B → $1.08B (-$1.58B)
67% less funds holding in top 10
Funds holding in top 10: 6 → 2 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$76.3M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$50.5M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$43.1M |
| 4 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$17.3M |
| 5 |
JP Morgan Chase
New York
|
+$16.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$44.2M |
| 2 |
Millennium Management
New York
|
-$36.5M |
| 3 |
TCP
Tourbillon Capital Partners
New York
|
-$34.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$32.2M |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
-$26.8M |
PTLA Hedge Fund Activity: Q1 2016 in Review
167 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q1 2016, worth a combined $1.08B — down 59% from $2.66B a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of PTLA and 19 opened new positions — a net loss of 22 holders — while 52 trimmed existing stakes and 75 added.
The largest buyer was Deerfield Management, adding an estimated $76.3M. The largest seller was Jennison Associates, exiting entirely with an estimated $44.2M sold.
- 167 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q1 2016, down from 190 in Q4 2015.
- Funds reported $1.08B of Portola Pharmaceuticals, Inc. stock for Q1 2016, down 59% quarter-over-quarter.
- 19 funds opened new Portola Pharmaceuticals, Inc. positions in Q1 2016 and 41 closed out, a net change of -22 holders.
- The largest Portola Pharmaceuticals, Inc. buyer in Q1 2016 was Deerfield Management, an estimated $76.3M added.
- The largest Portola Pharmaceuticals, Inc. seller in Q1 2016 was Jennison Associates, an estimated $44.2M sold.
Based on aggregated 13F filings for Q1 2016.